Laboratoire LESCUYER obtained a positive opinion from the EFSA that was unprecedented for a food supplement
Laboratoire LESCUYER has obtained an EFSA¹ positive opinion for a type 14 health claim for its product LIMICOL.
The European market is experiencing a historic moment since, hitherto, no food supplement had been granted a positive opinion for such a claim. Laboratoire LESCUYER is thus a pioneer.
Unique proof of efficacy recognized by a demanding authority
Obtaining EFSA approval is a lengthy and demanding process. The EFSA is not only the highest European authority with respect to food safety but is also one of the most demanding expert nutritional panels worldwide. A positive opinion from the EFSA is thus the highest scientific recognition possible at European level.
Through its positive opinion, EFSA has scientifically recognized the health benefits of LIMICOL: LIMICOL "reduces blood LDL cholesterol levels. A high LDL cholesterol level is a risk factor for the development of coronary heart disease".
An unprecedented and exclusive claim
LIMICOL is the first food supplement with data protection for a claim relating to reduction in a risk factor for a disease. As of the European Commission's final approval, Laboratoire LESCUYER will thus be the only company able to make that health claim for its exclusive and patented formula.
Scientific quality worthy of recognition
The positive opinion constitutes the fruit of 5 years of research which enabled submission of a very complete scientific dossier, including the results of 3 proprietary clinical trials, to the EFSA.
Laboratoire LESCUYER's medical and scientific team called on outside collaborators (biochemists, clinicians, toxicologists, biostatisticians) in order to collate the claim application dossier. The independent research groups conducted the 3 clinical trials at the highest level of scientific quality: randomized, double-blind, placebo-controlled studies that included a total of 184 volunteers. All the studies 2,3,4 have been published in international scientific journals, reflecting the quality of the results published.
Thanks to the research, LIMICOL is currently the only exclusive and patented food supplement whose efficacy is officially recognized by the European authorities.
First marketed in 2008, LIMICOL is a food supplement that combines plant extracts, red yeast rice and vitamins. In all, there are 8 active substances which act synergistically to naturally reduce high cholesterol levels.
The formula of LIMICOL includes artichoke extract, red yeast rice, sugar cane policosanol, garlic extract, maritime pine bark procyanidolic oligomers (PCO) and vitamins B2, B3 and E.
Efficacy proven by 3 clinical trials
The efficacy of LIMICOL with respect to reducing cholesterol levels was demonstrated by 3 clinical trials conducted on a total of 184 volunteers presenting with high cholesterol levels. As of the 1st month, daily intake of 3 LIMICOL tablets enabled a significant reduction of 15.3% ² in total cholesterol, 21.4% ² in LDL cholesterol and 15.4% ³ in
apolipoprotein B. The markers then remained stable over the following 3 months. After 4 months of supplementation, a 12.2% ² decrease in triglycerides was also observed.
Guarantee of good safety profile
The efficacy and uniqueness of the LIMICOL formula is based on the synergistic action of the selected active substances and on the precise strength of each ingredient.
Laboratoire LESCUYER deliberately chose to incorporate monacolin K (an active substance derived from red yeast rice) at a concentration of 2 mg per recommended daily dose while ensuring perfect efficacy. The strength, lower than the recommended dose, enables prevention of the muscle disorders generally observed and related to red yeast rice intake.
The excellent safety profile of LIMICOL was confirmed by 3 clinical trials.
About Laboratoire LESCUYER
Laboratoire LESCUYER, an expert in micronutrition, is a major player on the French food supplement market. The company was founded in 1994 by Dr. Jean-François LESCUYER. The company specializes in the formulation and marketing of very high quality food supplements. With 80 products and over 100 references, the company offers numerous ranges designed to protect and improve health. At the forefront of scientific research, the company has undertaken to develop innovative healthcare products that are both effective and safe. Its products are widely recognized and advised by numerous healthcare professionals.
¹EFSA Journal 2013;11(7):3327.
²Ogier N et al. Eur J Nutr. 2013 Mar;52(2):547-57.
³Barrat E et al. Int J Food Sci Nutr. 2013 Jul 2. [Epub ahead of print] - Clinical trial conducted by Biofortis.
4Barrat E et al. Eur J Nutr. 2013 ; 52(8):1843-52 - Clinical trial conducted by Biofortis.
Lucie Lecestre - firstname.lastname@example.org - (+33) 5 47 74 53 34
Download the press release.
Eur J Nutr. 2012 Dec 25. [Epub ahead of print]